Shares of Esperion Therapeutics Inc (NASDAQ:ESPR) have been assigned a consensus rating of “Buy” from the thirteen brokerages that are covering the firm. Seven equities research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $31.92.
A number of analysts have recently issued reports on ESPR shares. Royal Bank of Canada reiterated a “hold” rating and set a $15.00 target price on shares of Esperion Therapeutics in a report on Tuesday, January 3rd. Citigroup Inc set a $39.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a report on Monday, March 20th. Credit Suisse Group AG upgraded Esperion Therapeutics from an “underperform” rating to a “neutral” rating and set a $29.00 price target for the company in a report on Monday, March 20th. JPMorgan Chase & Co. upped their price target on Esperion Therapeutics from $22.00 to $50.00 in a report on Tuesday, March 21st. Finally, Zacks Investment Research cut Esperion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 24th.
Shares of Esperion Therapeutics (NASDAQ:ESPR) traded down 1.85% during trading on Friday, hitting $36.69. 528,042 shares of the company’s stock were exchanged. The company’s market cap is $827.54 million. Esperion Therapeutics has a 12-month low of $9.40 and a 12-month high of $48.21. The company has a 50-day moving average of $35.12 and a 200-day moving average of $19.23.
Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Wednesday, February 22nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.24) by $0.05. During the same period last year, the firm posted ($0.58) earnings per share. On average, equities analysts expect that Esperion Therapeutics will post ($6.08) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was first posted by BBNS and is owned by of BBNS. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://baseballnewssource.com/markets/esperion-therapeutics-inc-espr-receives-31-92-consensus-pt-from-analysts-updated/580704.html.
In other Esperion Therapeutics news, Director Gilbert S. Omenn purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, March 21st. The stock was bought at an average price of $42.26 per share, with a total value of $42,260.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $422,600. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Dov A. Md Goldstein sold 800,000 shares of the stock in a transaction on Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The disclosure for this sale can be found here. 35.40% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ESPR. BB Biotech AG boosted its position in shares of Esperion Therapeutics by 29.7% in the third quarter. BB Biotech AG now owns 1,308,542 shares of the biopharmaceutical company’s stock valued at $18,123,000 after buying an additional 300,000 shares in the last quarter. Paulson & CO. Inc. purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at $1,277,000. JPMorgan Chase & Co. boosted its position in shares of Esperion Therapeutics by 27.6% in the third quarter. JPMorgan Chase & Co. now owns 181,400 shares of the biopharmaceutical company’s stock valued at $2,512,000 after buying an additional 39,239 shares in the last quarter. J. Goldman & Co LP purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at $2,028,000. Finally, Keybank National Association OH purchased a new position in shares of Esperion Therapeutics during the fourth quarter valued at $159,000. 64.65% of the stock is owned by institutional investors and hedge funds.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with our FREE daily email newsletter.